1. Home
  2. Directory
  3. NPI Profile
  4. Prescriptions 1972564367

DR. NORMAN I MALDONADO MD
Prescription History 1972564367
Internal Medicine - Hematology & Oncology in San Juan, PR

NPI Status: Active since March 28, 2006

Contact Information

HOSPITAL DEL MAESTRO 2ND PISO
HOSPITAL DEL MAESTRO
SAN JUAN, PR
ZIP 00918
Phone: (787) 763-7365
Fax: (787) 763-0702

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. NORMAN I MALDONADO MD, an active Hematology & Oncology specialist practicing in San Juan, PR. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 89 documented patient claims. Among these therapy options, the most frequently utilized medication is Letrozole, which accounts for 36 claims alone.

Medication Index

H
I
L
P
R
No matching medications currently found on file.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 14.0
Days Supply 406
PR State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills36.0
Peer Average Days Supply1,065
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 61.3% less volume than the regional standard for practitioners inside PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $349.67 across this reporting matrix range.

Provider Avg Cost Per Claim

$29.14

State Avg Cost Per Claim

$30.88

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Ibrance

Generic Formulation: PalbociclibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 364
PR State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills48.1
Peer Average Days Supply1,343
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 72.9% less volume than the regional standard for practitioners inside PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $204,650.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,742.36

State Avg Cost Per Claim

$14,203.82

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Palbociclib is used to treat a certain type of breast cancer. It works by slowing or stopping the growth of cancer cells.

Letrozole

Generic Formulation: LetrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 36
30-Day Fills 44.0
Days Supply 1,320
PR State Average Benchmarks
Peer Average Claims42.0
Peer Average 30-Day Fills55.9
Peer Average Days Supply1,673
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $524.95 across this reporting matrix range.

Provider Avg Cost Per Claim

$14.58

State Avg Cost Per Claim

$13.10

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Prednisone

Generic Formulation: PrednisoneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 450
PR State Average Benchmarks
Peer Average Claims60.0
Peer Average 30-Day Fills62.0
Peer Average Days Supply1,242
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 75.0% less volume than the regional standard for practitioners inside PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $97.77 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.52

State Avg Cost Per Claim

$5.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Revlimid

Generic Formulation: LenalidomideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 364
PR State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills44.8
Peer Average Days Supply1,213
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 70.5% less volume than the regional standard for practitioners inside PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $231,824.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$17,832.68

State Avg Cost Per Claim

$18,378.12

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

Therapeutic Applications

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. NORMAN I MALDONADO MD provides transparency into local medical care patterns within San Juan, PR.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.